General
Preferred name
BUMETANIDE
Synonyms
Ro 10-6338 ()
PF 1593 ()
Bumetanida ()
S95008. ()
RO-10-6338 ()
Lixil ()
Ro-106338 ()
RO10-6338 ()
PF-1593 ()
Bumex ()
Betinex ()
PF1593 ()
S-95008. ()
Burinex ()
Bumetanide-d5 ()
P&D ID
PD001439
CAS
28395-03-1
1216739-35-3
Tags
available
drug
Approved by
FDA
First approval
1983
Drug indication
Congestive heart failure
Drug Status
approved
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PHARMACODYNAMICS Bumetanide is a loop diuretic of the sulfamyl category to treat heart failure. It is often used in patients in whom high doses of furosemide are ineffective. There is however no reason not to use bumetanide as a first choice drug. The main difference between the two substances is in bioavailability. Bumetanide has more predictable pharmacokinetic properties as well as clinical effect. In patients with normal renal function, bumetanide is 40 times more effective than furosemide.
DESCRIPTION Bumetanide is a loop diuretic drug. It inhibits NKCC1 (SLC12A2) tranporters in the brain and kidney-specific NKCC2 (SLC12A1) transporters in the thick ascending limb of Henle's loop. The latter action modulates water and electrolyte homeostasis and is reponsible for the drug's diuretic effects. (GtoPdb)
DESCRIPTION Bumetanide (Ro 10-6338; PF 1593), a highly potent loop diuretic, is a Na+-K+-Cl+ cotransporter (NKCC) blocker. Bumetanide is a selective NKCC1 inhibitor, but also inhibits NKCC2, with IC50s of 0.68 ¦ÌM and 4.0 ¦ÌM for hNKCC1A and hNKCC2A, respectively[1][2].
DESCRIPTION Na+/2Cl-/K+ (NKCC) symporter inhibitor; also GABAA antagonist (Tocris Bioactive Compound Library)
DESCRIPTION Na+/2Cl-/K+ (NKCC) symporter inhibitor (Tocriscreen Plus)
DESCRIPTION Potent inhibitor of the Na+-K+-2Cl- cotransporter; inhibits anthracene-9-carboxylic acid, a blocker of chloride channels (LOPAC library)
DESCRIPTION Bumetanide is a loop diuretic of the sulfamyl category to treat heart failure. It is often used in patients in whom high doses of furosemide are ineffective. Bumetanide interferes with renal cAMP and/or inhibits the sodium-potassium ATPase pump. Bumetanide also inhibits several isoforms of carbonic anhydrase. (Enamine Bioactive Compounds)
Compound Sets
34
AdooQ Bioactive Compound Library
A10167
Cayman Chemical Bioactives
14630
26773
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
CHEMBL1072
ChEMBL Drugs
CHEMBL1072
Concise Guide to Pharmacology 2017/18
4837
Concise Guide to Pharmacology 2019/20
4837
Concise Guide to Pharmacology 2021/22
4837
Concise Guide to Pharmacology 2023/24
4837
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB00887
DrugBank Approved Drugs
DB00887
DrugCentral
427
DrugCentral Approved Drugs
427
DrugMAP
DMRV7H0
DrugMAP Approved Drugs
DMRV7H0
DrugMatrix
Enamine Bioactive Compounds
EBC-04409
Enamine BioReference Compounds
Guide to Pharmacology
4837
LOPAC library
Mcule NIBR MoA Box Subset
MCULE-6802013568
MedChem Express Bioactive Compound Library
HY-17468
NCATS Inxight Approved Drugs
0Y2S3XUQ5H
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Bumetanide
The Spectrum Collection
Tocris Bioactive Compound Library
3108
Tocriscreen Plus
3108
External IDs
46
Properties
(calculated by RDKit )
Molecular Weight
364.11
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
3
Rotatable Bonds
8
Ring Count
2
Aromatic Ring Count
2
cLogP
3.04
TPSA
118.72
Fraction CSP3
0.24
Chiral centers
0.0
Largest ring
6.0
QED
0.62
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target Type
Transporters
Selectivity
Na+-K+-2Cl- cotransporter
MOA
bumetanide sensitive sodium-potassium-chloride cotransporter inhibitor
Inhibitor
Inhibits the sodium-potassium ATPase pump
solute carrier family member inhibitor
Target
Sodium/potassium-transporting ATPase subunit alpha-1
Solute carrier family 12 member 2
Sodium-(potassium)-chloride cotransporter 2
CFTR, GPR35, SLC12A1, SLC12A2, SLC12A4, SLC12A5
NKCC
Primary Target
Na+/K+/Cl- Symporter
Member status
member
Indication
edema, congestive heart failure
Therapeutic Class
Diuretics
Pathway
Membrane Transporter/Ion Channel
Source data